Search Bar & Filters
Found 19 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating TQB2102, an antibody-drug conjugate designed to target Human Epidermal Growth Factor Receptor 2 HER2 positive tumor cells, in patients with recurrent or metastatic advanced gynecological tumors. This Phase 2 study aims to assess the safety and effectiveness of TQB2102 in this patient population, addressing the need for new treatments after unsuccessful platinum-based chemotherapy. Participants will receive TQB2102 through intravenous infusion every three weeks, with each treatment cycle lasting 21 days. This investigational drug combines a humanized antibody with a potent drug payload to specifically attack tumor cells. The study includes monitoring for adverse events and anti-drug antibodies during treatment and follow-up. During the trial, participants will undergo regular assessments including tumor measurements to evaluate overall response rate, duration of remission, progression-free survival, overall survival, and disease control rate for up to 12 to 17 months. Safety evaluations will continue until 28 days after the last dose or the start of new cancer therapies. Blood samples for anti-drug antibody testing will be collected at specific treatment cycles and after treatment completion. The total involvement period depends on individual treatment duration and follow-up schedules.
Actively Recruiting
Researchers are evaluating the effectiveness of early treatment with BXOS110 injection in reducing disability for patients who have had an acute ischaemic stroke. This phase 3 clinical trial compares BXOS110 to a placebo to better understand its safety and impact when given within three hours of stroke onset. The study includes adults aged 18 to 85 diagnosed with acute ischaemic stroke, with specific neurological and functional criteria for participation. Participants are randomly assigned to one of two groups one receiving a single intravenous infusion of BXOS110 at a dose of 3.0 mgkg up to 300 mg, and the other receiving a placebo infusion of the same volume and dose schedule. The study is double-blind and placebo-controlled, meaning neither participants nor researchers know which treatment is given. The trial consists of a screening and baseline phase, a treatment phase with immediate administration of the study drug, followed by a follow-up period with evaluations on days 2, 3, 10 or at discharge, day 30, and day 90 after treatment. Throughout the study, participants undergo assessments to measure disability and neurological function, including the modified Rankin Scale mRS, NIH Stroke Scale NIHSS, Barthel Index BI, and EQ-5D quality of life questionnaire. The main outcome measured is the proportion of patients achieving an mRS score of 0 to 2 on day 90, indicating good recovery. Safety and efficacy are monitored closely during follow-up visits and at discharge. The total study duration includes screening, treatment, and a 90-day follow-up period to assess outcomes and safety.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are studying the safety, tolerability, and effectiveness of elecoglipron alone or combined with dapagliflozin compared to placebo in adults with type 2 diabetes mellitus T2DM who are not well controlled with lifestyle changes or other glucose-lowering medications. This Phase III trial aims to better understand how these treatments impact blood sugar control and other health measures. Participants will be randomly assigned to one of four groups elecoglipron at dose level 1 with dapagliflozin placebo, elecoglipron at dose level 2 with dapagliflozin placebo, elecoglipron at one of the studied doses combined with dapagliflozin, or matching placebos for both drugs. All medications are taken orally once daily. The study lasts 40 weeks, during which participants receive their assigned treatment and are monitored. During the study, participants will undergo regular assessments including measurements of blood sugar control HbA1c, body weight, and blood pressure from baseline to Week 40. Researchers will also track the achievement of specific blood sugar targets, weight loss percentages, and the time before needing additional diabetes medication. Safety and tolerability will be monitored throughout the treatment period. The total participation duration is approximately 40 weeks.
Actively Recruiting
Researchers are studying the effectiveness, safety, and tolerability of combining elecoglipron and dapagliflozin compared to using each drug alone in adults with type 2 diabetes mellitus T2DM who are not well controlled by lifestyle changes or other diabetes medications. This phase III trial aims to understand how well these treatments manage blood sugar levels in this population. Participants will be randomly assigned to one of five groups two different doses of elecoglipron combined with dapagliflozin, two doses of elecoglipron combined with a placebo matching dapagliflozin, or dapagliflozin alone with a placebo matching elecoglipron. All medications are taken orally once daily. The study uses a double-blind, parallel-group design to compare these treatments over 40 weeks. During the study, participants will have their blood sugar control measured primarily by changes in Hemoglobin A1c HbA1c from the start to week 40. Secondary measures include body weight changes, fasting plasma glucose, blood pressure, and time to starting rescue medication. Regular assessments will monitor safety and treatment effects throughout the trial period, which lasts about 40 weeks.
Actively Recruiting
Researchers are studying brenipatide LY3537031 to evaluate its safety, side effects, and effectiveness in adults with Irritable Bowel Syndrome-Constipation IBS-C. The study compares brenipatide given by injection under the skin to a placebo in a phase 2 clinical trial. Participants must meet specific IBS-C criteria and have significant abdominal pain to join. Participants receive the study drug or placebo through subcutaneous injection. The trial lasts about 36 weeks, with treatment and monitoring occurring during this period. The study is randomized and double-blind, meaning neither participants nor researchers know who receives the drug or placebo. During the study, participants will keep a daily diary to track symptoms like abdominal pain and bowel movements. Researchers will measure the percentage of weeks participants respond to treatment based on clinical criteria between weeks 9 and 16. Safety and side effects will also be closely monitored throughout the trial.
Actively Recruiting
Researchers are evaluating the safety, side effects, and effectiveness of brenipatide LY3537031 in adults with Irritable Bowel Syndrome-Diarrhea IBS-D. This study compares brenipatide given under the skin to a placebo and aims to understand how well the drug is tolerated and how it impacts symptoms in participants aged 18 to 75. The trial is a randomized, double-blind, placebo-controlled Phase 2 study sponsored by Eli Lilly and Company. Participants receive either brenipatide or placebo, both administered subcutaneously. The study follows a parallel design where different groups receive either the experimental drug or the placebo. Treatment and evaluation last approximately 36 weeks, with key outcome measurements focused on symptom responses between weeks 9 to 16 and up to week 24. During the study, participants will record symptoms daily in an electronic diary, including abdominal pain and stool consistency. Researchers will monitor safety, side effects, and symptom changes through these reports and scheduled assessments. The main outcome is the percentage of days participants show significant symptom improvement during the critical weeks of treatment. The study includes a full follow-up period to assess lasting effects and safety throughout the 36 weeks.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of lebrikizumab, a drug given by injection, in people aged 12 and older with chronic rhinosinusitis and nasal polyps who are also treated with intranasal corticosteroids. This phase 3 trial aims to improve symptoms like nasal congestion and polyp size while monitoring participant safety over about 18 months. Participants receive lebrikizumab injections on different schedules or placebo injections, all along with standard intranasal corticosteroid spray. Adolescents aged 12 to under 18 who weigh at least 40 kg are assigned to open-label lebrikizumab treatment. The study includes multiple groups receiving injections every 2, 4, or 8 weeks to compare outcomes. During the study, participants will undergo assessments including nasal congestion scoring, endoscopic evaluation of nasal polyps, sinus imaging, lung function tests, and symptom questionnaires from the start through 24 weeks. Safety and symptom changes are closely monitored, and the total study duration is approximately 18 months.
Actively Recruiting
Researchers are conducting an open-label phase 1 trial to evaluate the safety, tolerability, and pharmacokinetics of the oral drug ABSK-011 in patients with advanced solid tumors. The study includes an escalation part to determine the recommended dose for expansion and an expansion part focusing on patients with advanced liver cancer HCC who have FGF19 overexpression. The trial also explores preliminary antitumor activity of ABSK-011 in this group. During the escalation phase, participants receive a single dose of ABSK-011 followed by a 1-day break to assess pharmacokinetics before continuing daily or twice-daily dosing in 28-day cycles. Dose increases follow a 33 design except for an accelerated titration cohort. In the expansion phase, patients are treated at the recommended dose determined from escalation. A food effect cohort may also be studied. Participants undergo regular monitoring including physical exams, ECOG performance status, ECGs, echocardiograms, and vital signs throughout the study, lasting about six months on average. The team tracks dose-limiting toxicities, adverse events, and treatment adjustments. Pharmacokinetic measures are collected during the first treatment cycle. Tumor response and disease control are also assessed over the study period. Follow-up includes safety and tolerability evaluations after treatment completion.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of elecoglipron compared with a placebo to help manage weight in adults living with obesity or overweight, including those with or without type 2 diabetes mellitus. This Phase III, randomized, double-blind, placebo-controlled study involves multiple centers and aims to assess elecogliprons impact on weight management over time. Participants will be randomly assigned to receive either one of two doses of elecoglipron or a matching placebo tablet taken once daily, alongside diet and exercise. The study will last for 52 weeks, during which efficacy and safety will be continuously evaluated. The study includes adults with a body mass index BMI of 28 kgm or higher, or those with a BMI between 24 and less than 28 kgm with at least one weight-related health issue. During the study, participants will undergo regular assessments including body weight measurements and waist circumference at baseline and at Week 52. Researchers will monitor changes in body weight, specifically the percent change from the start to Week 52, and the number of participants achieving at least 5% and 10% weight loss. Safety evaluations will be conducted throughout the trial to ensure participant well-being.
1-10 of 19
1